Download PDF
Semin Thromb Hemost 2022; 48(05): 514-528
DOI: 10.1055/s-0042-1743467
Review Article

Systemic Antiangiogenic Therapies for Bleeding in Hereditary Hemorrhagic Telangiectasia: A Practical, Evidence-Based Guide for Clinicians

Hanny Al-Samkari
1   Division of Hematology Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
› Author Affiliations Funding None.
› Further Information
    Permissions and Reprints

Abstract

Management of bleeding in hereditary hemorrhagic telangiectasia (HHT), the second most common hereditary bleeding disorder in the world, is currently undergoing a paradigm shift. Disease-modifying antiangiogenic therapies capable of achieving durable hemostasis via inducing telangiectasia regression have emerged as a highly effective and safe modality to treat epistaxis and gastrointestinal bleeding in HHT. While evidence to date is incomplete and additional studies are ongoing, patients presently in need are being treated with antiangiogenic agents off-label. Intravenous bevacizumab, oral pazopanib, and oral thalidomide are the three targeted primary angiogenesis inhibitors, with multiple studies describing both reassuring safety and impressive effectiveness in the treatment of moderate-to-severe HHT-associated bleeding. However, at present there is a paucity of guidance in the literature, including the published HHT guidelines, addressing the practical aspects of antiangiogenic therapy for HHT in clinical practice. This review article and practical evidence-based guide aims to fill this unaddressed need, synthesizing published data on the use of antiangiogenic agents in HHT, relevant data for their use outside of HHT, and expert guidance where evidence is lacking. After a brief review of principles of bleeding therapy in HHT, guidance on hematologic support with iron and blood products, and alternatives to antiangiogenic therapy, this article examines each of the aforementioned antiangiogenic agents in detail, including patient selection, initiation, monitoring, toxicity management, and discontinuation. With proper, educated use of antiangiogenic therapies in HHT, patients with even the most severe bleeding manifestations can achieve durable hemostasis with minimal side-effects, dramatically improving health-related quality of life and potentially altering the disease course.

Keywords

hereditary hemorrhagic telangiectasia - Osler–Weber–Rendu - treatment guidelines - bevacizumab - pazopanib - pomalidomide - thalidomide - angiogenesis - epistaxis - gastrointestinal bleeding

Authors' Contributions

H. Al-Samkari was responsible for all aspects of the manuscript, from conception to completion.




Publication History

Article published online:
28 February 2022

© 2022. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Kritharis A, Al-Samkari H, Kuter DJ. Hereditary hemorrhagic telangiectasia: diagnosis and management from the hematologist's perspective. Haematologica 2018; 103 (09) 1433-1443
    CrossrefPubMedGoogle Scholar
  • 2 Kasthuri RS, Montifar M, Nelson J, Kim H, Lawton MT, Faughnan ME. Brain Vascular Malformation Consortium HHT Investigator Group. Prevalence and predictors of anemia in hereditary hemorrhagic telangiectasia. Am J Hematol 2017; (epub ahead of print) DOI: 10.1002/ajh.24832.
    CrossrefPubMedGoogle Scholar
  • 3 Faughnan ME, Palda VA, Garcia-Tsao G. et al; HHT Foundation International - Guidelines Working Group. International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. J Med Genet 2011; 48 (02) 73-87
    CrossrefPubMedGoogle Scholar
  • 4 Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246 (4935): 1306-1309
    CrossrefPubMedGoogle Scholar
  • 5 Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989; 161 (02) 851-858
    CrossrefPubMedGoogle Scholar
  • 6 Cirulli A, Liso A, D'Ovidio F. et al. Vascular endothelial growth factor serum levels are elevated in patients with hereditary hemorrhagic telangiectasia. Acta Haematol 2003; 110 (01) 29-32
    CrossrefPubMedGoogle Scholar
  • 7 Al-Samkari H. Hereditary hemorrhagic telangiectasia: systemic therapies, guidelines, and an evolving standard of care. Blood 2020; 137 (07) 888-895
    PubMedGoogle Scholar
  • 8 Faughnan ME, Mager JJ, Hetts SW. et al. Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia. Ann Intern Med 2020; 173 (12) 989-1001
    Google Scholar
  • 9 Hoag JB, Terry P, Mitchell S, Reh D, Merlo CA. An epistaxis severity score for hereditary hemorrhagic telangiectasia. Laryngoscope 2010; 120 (04) 838-843
    CrossrefPubMedGoogle Scholar
  • 10 Yin LX, Reh DD, Hoag JB. et al. The minimal important difference of the epistaxis severity score in hereditary hemorrhagic telangiectasia. Laryngoscope 2016; 126 (05) 1029-1032
    CrossrefPubMedGoogle Scholar
  • 11 Al-Samkari H, Naik RP, Zakai NA. A hematologic support score for longitudinal measurement of blood and iron requirements in hereditary hemorrhagic telangiectasia and other chronic bleeding disorders. Res Pract Thromb Haemost 2020; 4 (08) 1340-1342
    CrossrefPubMedGoogle Scholar
  • 12 Bernhart FW, Skeggs L. The iron content of crystalline human hemoglobin. J Biol Chem 1943; 147: 19
    CrossrefPubMedGoogle Scholar
  • 13 Elgailani IEH, Alsakka MM. Determination of iron content in different hemoglobin samples from some patients by UV-visible spectrophotometer. Adv Anal Chem 2016; 6 (02) 35-40
    PubMedGoogle Scholar
  • 14 Sabbà C, Pasculli G, Lenato GM. et al. Hereditary hemorrhagic telangiectasia: clinical features in ENG and ALK1 mutation carriers. J Thromb Haemost 2007; 5 (06) 1149-1157
    CrossrefPubMedGoogle Scholar
  • 15 van Tuyl SA, Letteboer TG, Rogge-Wolf C. et al. Assessment of intestinal vascular malformations in patients with hereditary hemorrhagic teleangiectasia and anemia. Eur J Gastroenterol Hepatol 2007; 19 (02) 153-158
    CrossrefPubMedGoogle Scholar
  • 16 Grève E, Moussata D, Gaudin JL. et al. High diagnostic and clinical impact of small-bowel capsule endoscopy in patients with hereditary hemorrhagic telangiectasia with overt digestive bleeding and/or severe anemia. Gastrointest Endosc 2010; 71 (04) 760-767
    Google Scholar
  • 17 Canzonieri C, Centenara L, Ornati F. et al. Endoscopic evaluation of gastrointestinal tract in patients with hereditary hemorrhagic telangiectasia and correlation with their genotypes. Genet Med 2014; 16 (01) 3-10
    Google Scholar
  • 18 Kjeldsen AD, Kjeldsen J. Gastrointestinal bleeding in patients with hereditary hemorrhagic telangiectasia. Am J Gastroenterol 2000; 95 (02) 415-418
    Google Scholar
  • 19 Iyer VN, Brinjikji W, Apala D. et al. Impact of age on outcomes in hospitalized patients with hereditary hemorrhagic telangiectasia. Adv Hematol 2018; 2018: 4798425
    PubMedGoogle Scholar
  • 20 Plauchu H, de Chadarévian JP, Bideau A, Robert JM. Age-related clinical profile of hereditary hemorrhagic telangiectasia in an epidemiologically recruited population. Am J Med Genet 1989; 32 (03) 291-297
    CrossrefPubMedGoogle Scholar
  • 21 Hanks JE, Hunter D, Goding Jr GS, Boyer HC. Complications from office sclerotherapy for epistaxis due to hereditary hemorrhagic telangiectasia (HHT or Osler-Weber-Rendu). Int Forum Allergy Rhinol 2014; 4 (05) 422-427
    CrossrefPubMedGoogle Scholar
  • 22 Rotenberg B, Noyek S, Chin CJ. Radiofrequency ablation for treatment of hereditary hemorrhagic telangiectasia lesions: “How I do it”. Am J Rhinol Allergy 2015; 29 (03) 226-227
    CrossrefPubMedGoogle Scholar
  • 23 Geisthoff U, Nguyen HL, Lefering R, Maune S, Thangavelu K, Droege F. Trauma can induce telangiectases in hereditary hemorrhagic telangiectasia. J Clin Med 2020; 9 (05) E1507
    CrossrefPubMedGoogle Scholar
  • 24 Levine CG, Ross DA, Henderson KJ, Leder SB, White Jr RI. Long-term complications of septal dermoplasty in patients with hereditary hemorrhagic telangiectasia. Otolaryngol Head Neck Surg 2008; 138 (06) 721-724
    CrossrefPubMedGoogle Scholar
  • 25 Lund VJ, Darby Y, Rimmer J, Amin M, Husain S. Nasal closure for severe hereditary haemorrhagic telangiectasia in 100 patients. The Lund modification of the Young's procedure: a 22-year experience. Rhinology 2017; 55 (02) 135-141
    CrossrefPubMedGoogle Scholar
  • 26 Whitehead KJ, Sautter NB, McWilliams JP. et al. Effect of topical intranasal therapy on epistaxis frequency in patients with hereditary hemorrhagic telangiectasia: a randomized clinical trial. JAMA 2016; 316 (09) 943-951
    CrossrefPubMedGoogle Scholar
  • 27 Stokes P, Rimmer J. Intranasal bevacizumab in the treatment of HHT-related epistaxis: a systematic review. Rhinology 2018; 56 (01) 3-10
    CrossrefPubMedGoogle Scholar
  • 28 Vase P. Estrogen treatment of hereditary hemorrhagic telangiectasia. A double-blind controlled clinical trial. Acta Med Scand 1981; 209 (05) 393-396
    CrossrefPubMedGoogle Scholar
  • 29 Jeanneret S, Regazzoni L, Favrat B. Rendu-Osler disease: treatment with oestrogen/progestagen versus octreotide. BMJ Case Rep 2011; 2011: bcr1120103534
    CrossrefPubMedGoogle Scholar
  • 30 Kettaneh A, Eclache V, Fain O. et al. Pica and food craving in patients with iron-deficiency anemia: a case-control study in France. Am J Med 2005; 118 (02) 185-188
    CrossrefPubMedGoogle Scholar
  • 31 Vaucher P, Druais PL, Waldvogel S, Favrat B. Effect of iron supplementation on fatigue in nonanemic menstruating women with low ferritin: a randomized controlled trial. CMAJ 2012; 184 (11) 1247-1254
    CrossrefPubMedGoogle Scholar
  • 32 Trost LB, Bergfeld WF, Calogeras E. The diagnosis and treatment of iron deficiency and its potential relationship to hair loss. J Am Acad Dermatol 2006; 54 (05) 824-844
    CrossrefPubMedGoogle Scholar
  • 33 Haas JD, Brownlie IV T. Iron deficiency and reduced work capacity: a critical review of the research to determine a causal relationship. J Nutr 2001;131(2S-2):676S–688S, discussion 688S–690S
    PubMedGoogle Scholar
  • 34 Livesey JA, Manning RA, Meek JH. et al. Low serum iron levels are associated with elevated plasma levels of coagulation factor VIII and pulmonary emboli/deep venous thromboses in replicate cohorts of patients with hereditary haemorrhagic telangiectasia. Thorax 2012; 67 (04) 328-333
    CrossrefPubMedGoogle Scholar
  • 35 Stoffel NU, Uyoga MA, Mutuku FM. et al. Iron deficiency anemia at time of vaccination predicts decreased vaccine response and iron supplementation at time of vaccination increases humoral vaccine response: a birth cohort study and a randomized trial follow-up study in Kenyan infants. Front Immunol 2020; 11: 1313
    CrossrefPubMedGoogle Scholar
  • 36 Ganzoni AM. Intravenous iron-dextran: therapeutic and experimental possibilities. [in German]. Schweiz Med Wochenschr 1970; 100 (07) 301-303
    PubMedGoogle Scholar
  • 37 Fernandez-L A, Garrido-Martin EM, Sanz-Rodriguez F. et al. Therapeutic action of tranexamic acid in hereditary haemorrhagic telangiectasia (HHT): regulation of ALK-1/endoglin pathway in endothelial cells. Thromb Haemost 2007; 97 (02) 254-262
    Article in Thieme ConnectPubMedGoogle Scholar
  • 38 Gaillard S, Dupuis-Girod S, Boutitie F. et al; ATERO Study Group. Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: a European cross-over controlled trial in a rare disease. J Thromb Haemost 2014; 12 (09) 1494-1502
    CrossrefPubMedGoogle Scholar
  • 39 Geisthoff UW, Seyfert UT, Kübler M, Bieg B, Plinkert PK, König J. Treatment of epistaxis in hereditary hemorrhagic telangiectasia with tranexamic acid - a double-blind placebo-controlled cross-over phase IIIB study. Thromb Res 2014; 134 (03) 565-571
    CrossrefPubMedGoogle Scholar
  • 40 Zaffar N, Ravichakaravarthy T, Faughnan ME, Shehata N. The use of anti-fibrinolytic agents in patients with HHT: a retrospective survey. Ann Hematol 2015; 94 (01) 145-152
    CrossrefPubMedGoogle Scholar
  • 41 Beckman JD, Li Q, Hester ST, Leitner O, Smith KL, Kasthuri RS. Integration of clinical parameters, genotype and epistaxis severity score to guide treatment for hereditary hemorrhagic telangiectasia associated bleeding. Orphanet J Rare Dis 2020; 15 (01) 185
    CrossrefPubMedGoogle Scholar
  • 42 Chaturvedi S, Clancy M, Schaefer N, Oluwole O, McCrae KR. Depression and post-traumatic stress disorder in individuals with hereditary hemorrhagic telangiectasia: a cross-sectional survey. Thromb Res 2017; 153: 14-18
    CrossrefPubMedGoogle Scholar
  • 43 Parambil JG, Gossage JR, McCrae KR. et al. Pazopanib for severe bleeding and transfusion-dependent anemia in hereditary hemorrhagic telangiectasia. Angiogenesis 2021; (epub ahead of print) DOI: 10.1007/s10456-021-09807-4.
    CrossrefPubMedGoogle Scholar
  • 44 Al-Samkari H. Hereditary hemorrhagic telangiectasia: systemic therapies, guidelines, and an evolving standard of care. Blood 2021; 137 (07) 888-895
    CrossrefPubMedGoogle Scholar
  • 45 Al-Samkari H, Kasthuri RS, Parambil JG. et al. An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study. Haematologica 2021; 106 (08) 2161-2169
    CrossrefPubMedGoogle Scholar
  • 46 Iyer VN, Apala DR, Pannu BS. et al. Intravenous bevacizumab for refractory hereditary hemorrhagic telangiectasia-related epistaxis and gastrointestinal bleeding. Mayo Clin Proc 2018; 93 (02) 155-166
    CrossrefPubMedGoogle Scholar
  • 47 Al-Samkari H, Albitar HA, Olitsky SE, Clancy MS, Iyer VN. Systemic bevacizumab for high-output cardiac failure in hereditary hemorrhagic telangiectasia: an international survey of HHT centers. Orphanet J Rare Dis 2019; 14 (01) 256
    CrossrefPubMedGoogle Scholar
  • 48 Dupuis-Girod S, Ginon I, Saurin JC. et al. Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. JAMA 2012; 307 (09) 948-955
    CrossrefPubMedGoogle Scholar
  • 49 Al-Samkari H, Albitar HA, Olitsky SE, Clancy MS, Iyer VN. An international survey to evaluate systemic bevacizumab for chronic bleeding in hereditary haemorrhagic telangiectasia. Haemophilia 2020; 26 (06) 1038-1045
    CrossrefPubMedGoogle Scholar
  • 50 Albitar HAH, Almodallal Y, Gallo De Moraes A. et al. Intravenous bevacizumab in hereditary hemorrhagic telangiectasia-related bleeding and high-output cardiac failure: significant inter-individual variability in the need for maintenance therapy. Mayo Clin Proc 2020; 95 (08) 1604-1612
    CrossrefPubMedGoogle Scholar
  • 51 Guilhem A, Fargeton AE, Simon AC. et al. Intra-venous bevacizumab in hereditary hemorrhagic telangiectasia (HHT): a retrospective study of 46 patients. PLoS One 2017; 12 (11) e0188943
    CrossrefPubMedGoogle Scholar
  • 52 Faughnan ME, Gossage JR, Chakinala MM. et al. Pazopanib may reduce bleeding in hereditary hemorrhagic telangiectasia. Angiogenesis 2019; 22 (01) 145-155
    CrossrefPubMedGoogle Scholar
  • 53 Lebrin F, Srun S, Raymond K. et al. Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia. Nat Med 2010; 16 (04) 420-428
    CrossrefPubMedGoogle Scholar
  • 54 Peng HL, Yi YF, Zhou SK, Xie SS, Zhang GS. Thalidomide effects in patients with hereditary hemorrhagic telangiectasia during therapeutic treatment and in Fli-EGFP Transgenic Zebrafish Model. Chin Med J (Engl) 2015; 128 (22) 3050-3054
    CrossrefPubMedGoogle Scholar
  • 55 Fang J, Chen X, Zhu B. et al. Thalidomide for epistaxis in patients with hereditary hemorrhagic telangiectasia: a preliminary study. Otolaryngol Head Neck Surg 2017; 157 (02) 217-221
    CrossrefPubMedGoogle Scholar
  • 56 Invernizzi R, Quaglia F, Klersy C. et al. Efficacy and safety of thalidomide for the treatment of severe recurrent epistaxis in hereditary haemorrhagic telangiectasia: results of a non-randomised, single-centre, phase 2 study. Lancet Haematol 2015; 2 (11) e465 –e473
    CrossrefPubMedGoogle Scholar
  • 57 Hosman A, Westermann CJ, Snijder R, Disch F, Mummery CL, Mager JJ. Follow-up of thalidomide treatment in patients with hereditary haemorrhagic telangiectasia. Rhinology 2015; 53 (04) 340-344
    CrossrefPubMedGoogle Scholar
  • 58 Baysal M, Ümit EG, Kırkızlar HO, Özdöver AC, Demir AM. Thalidomide for the management of bleeding episodes in patients with hereditary hemorrhagic telangiectasia: effects on epistaxis severity score and quality of life. Turk J Haematol 2019; 36 (01) 43-47
    CrossrefPubMedGoogle Scholar
  • 59 Buscarini E, Botella LM, Geisthoff U. et al; VASCERN-HHT. Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia. Orphanet J Rare Dis 2019; 14 (01) 28
    CrossrefPubMedGoogle Scholar
  • 60 Al-Samkari H. Systemic bevacizumab for hereditary hemorrhagic telangiectasia: considerations from observational studies. Otolaryngol Head Neck Surg 2019; 160 (02) 368
    CrossrefPubMedGoogle Scholar
  • 61 Al-Samkari H, Kritharis A, Rodriguez-Lopez JM, Kuter DJ. Systemic bevacizumab for the treatment of chronic bleeding in hereditary haemorrhagic telangiectasia. J Intern Med 2019; 285 (02) 223-231
    CrossrefPubMedGoogle Scholar
  • 62 US FDA. Avastin (Bevacizumab) Prescribing Information 2017
  • 63 Izzedine H, Massard C, Spano JP, Goldwasser F, Khayat D, Soria JC. VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management. Eur J Cancer 2010; 46 (02) 439-448
    CrossrefPubMedGoogle Scholar
  • 64 Ostendorf T, Kunter U, Eitner F. et al. VEGF(165) mediates glomerular endothelial repair. J Clin Invest 1999; 104 (07) 913-923
    CrossrefPubMedGoogle Scholar
  • 65 Votrient (pazopanib) prescribing information. Novartis 2009
    PubMed
  • 66 Bauditz J, Schachschal G, Wedel S, Lochs H. Thalidomide for treatment of severe intestinal bleeding. Gut 2004; 53 (04) 609-612
    CrossrefPubMedGoogle Scholar
  • 67 Samour M, Saygin C, Abdallah R, Kundu S, McCrae KR. Pomalidomide in hereditary hemorrhagic telangiectasia: interim results of a Phase I study. Blood 2016; 128 (22) 210
    CrossrefPubMedGoogle Scholar
  • 68 US FDA. Thalidomide (Thalomid) Prescribing Information 2021
    Google Scholar